Approval was supported by the single-arm, multicenter FELIX trial, which enrolled patients with relapsed or refractory CD19-positive B-cell ALL. Among the 65 patients evaluable for efficacy ...

a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas, Haematologica (2024). DOI: 10.3324/haematol.

Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease pathogenesis. In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...

The fourth and final advantage would be rapid recovery of healthy B-cells. Consider that with other therapies like CD19 inhibitors or CD20 inhibitors, it can take a patient 6 months or more to see ...

"Targeting CD19+ B cells with Uplizna has proven to be a highly effective approach to help address the pathophysiology of IgG4-RD," said John Stone, MD, MPH, principal investigator of the MITIGATE ...

Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients ...

Blinatumomab (Blincyto) with chemotherapy is available on the NHS. It is a possible treatment for Philadelphia-chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in ...